Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222 (16 Aug 2022)
Statement on Deviation or Variation of funds raised through Rights Issue for the quarter ended 30th June, 2022
Wockhardt’s FY22 Revenue grew by 17% over FY21. Long Term Debt reduced by Rs 450 Cr. Successful Rights Issue of Rs.748 Cr.
